PORTSMOUTH, N.H. and LONDON and MELBOURNE, Australia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- In the most recent of a series of significant clinical milestones, Global Kinetics’ innovative wearable technology, the Personal KinetiGraph™ (PKG™), has been recommended by two separate expert panels for routine management of Parkinson’s disease. The publications follow on the heels of the recent announcement by the company that the American Medical Association (AMA) has issued a set of new Category III Current Procedural Terminology® (CPT®) codes that become effective on January 1, 2019.
Until recently, Parkinson’s disease has been one of the few chronic diseases still treated via subjective observation of symptomology. That is set to change as the PKG system is used by clinicians around the world to provide clinically validated continuous, objective measures of the distinguishing movement symptoms of Parkinson’s.
The two new landmark publications reflect the expert medical opinion of internationally recognized movement disorder specialists on the utilization of the PKG measurements to improve clinical management of Parkinson’s disease. The groups convened to examine the ideal objective measurement tool and clinical utility of the PKG in routine assessment and care of Parkinson’s patients.
Ad Statistics
Times Displayed: 112561
Times Visited: 6722 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
The first publication, titled “Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease,” was published online in Nature journal npj Parkinson’s Disease and can be found at https://www.nature.com/articles/s41531-018-0051-7. The second publication, titled “Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease: recommendations from an expert panel,” was published online in Expert Review of Neurotherapeutics, http://www.tandfonline.com/loi/iern20.
Key findings of these publications include:
1. The PKG is uniquely positioned to provide a continuous objective measure of patient symptoms, including bradykinesia, which is both treatment responsive and the clearest indicator of underlying pathological degeneration.
Bradykinesia means slowness of movement, which is related to the loss of dopamine responsiveness in brain cells. Unlike more obvious and commonly associated symptoms such as dyskinesia (a response to standard treatments for Parkinson’s) and tremor, bradykinesia is often difficult for a patient to identify and for a doctor to assess.
